Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke.

BACKGROUND Certain patients experience muscle-related adverse effects after taking atorvastatin. Genetic factors play an important role in the occurrence of statin-induced myopathy. AIM We aimed to identify genetic variants associated with statin-induced myotoxicity. METHODS We prospectively enrolled 1,102 acute ischemic stroke patients who underwent atorvastatin treatment for the first time after admission. Patients were separated into case and control groups after a follow-up of 3 months. We used a biochemical definition of myopathy consisting of serum creatine kinase values more than ten times the upper limit of normal for the reference laboratory (150 U/L). Fifty single nucleotide polymorphisms (SNPs) from seven genes of ABCB1, CoQ2, HTR3B, RYR2, CYP3A5, HTR7 and SLCO1B1 were selected and genotyped. The effects of genetic polymorphisms on myopathy were observed. RESULTS 61 cases and 110 controls were recruited in the study. Compared with the controls, the cases had a significant higher mutant frequency of the allele A (ABCB1, rs2373588) (OR = 2.01, 95%CI = 1.10-3.67, P = 0.001) and a significant lower mutant frequency of the allele A (SLCO1B1, rs976754) (OR = 1.85, 95%CI = 1.12-3.03, P = 0.042). Genotypes or alleles of the other SNPs had no significant difference between the two groups (P > 0.05). CONCLUSION Our findings reveal that SLCO1B1 and ABCB1 genetic variants are associated with statin-induced myopathy. These are valuable biomarkers for the evaluation of atorvastatin safety.

[1]  L. Salazar,et al.  Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects , 2018, Journal of clinical pharmacy and therapeutics.

[2]  Shi-long Zhong,et al.  SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study , 2017, European Journal of Clinical Pharmacology.

[3]  Y. Li,et al.  Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males , 2017, European journal of drug metabolism and pharmacokinetics.

[4]  P. Thompson,et al.  Statin-Associated Side Effects. , 2016, Journal of the American College of Cardiology.

[5]  F. Gao,et al.  Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting , 2016, PloS one.

[6]  Sang-Heon Cho,et al.  Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid , 2015, Pharmacogenetics and genomics.

[7]  Y. Li,et al.  Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. , 2015, British journal of clinical pharmacology.

[8]  J. Hubacek,et al.  Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. , 2015, European journal of internal medicine.

[9]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[10]  P. Thompson,et al.  A systematic review of statin-induced muscle problems in clinical trials. , 2014, American heart journal.

[11]  P. Ridker,et al.  Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. , 2013, American heart journal.

[12]  T. Andersson,et al.  Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects , 2013, Clinical pharmacology and therapeutics.

[13]  R. Kim,et al.  Impact of genetic variation in OATP transporters to drug disposition and response. , 2013, Drug metabolism and pharmacokinetics.

[14]  T. Brennan,et al.  Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing , 2012, Journal of personalized medicine.

[15]  P. Thompson,et al.  Effect of Statins on Skeletal Muscle: Exercise, Myopathy, and Muscle Outcomes , 2012, Exercise and sport sciences reviews.

[16]  M. Hayden,et al.  Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.

[17]  Matthew K Ito,et al.  Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. , 2012, Journal of clinical lipidology.

[18]  J. Krieger,et al.  SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia , 2012, European Journal of Clinical Pharmacology.

[19]  Y. Khader,et al.  Prevalence and risk factors of muscle complications secondary to statins , 2011, Muscle & nerve.

[20]  Beth Cobb,et al.  Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. , 2011, Molecular genetics and metabolism.

[21]  P. Walker,et al.  The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. , 2011, Journal of clinical lipidology.

[22]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[23]  M. Tarnopolsky,et al.  Metabolic Myopathies Discovered During Investigations of Statin Myopathy , 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[24]  A. Windemuth,et al.  Physiogenomic association of statin‐related myalgia to serotonin receptors , 2007, Muscle & nerve.

[25]  B. Miskie,et al.  Genetic determinants of statin intolerance , 2007, Lipids in Health and Disease.

[26]  A. Åsberg,et al.  Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several‐fold in patients with atorvastatin‐induced myopathy , 2006, Clinical pharmacology and therapeutics.